Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder |
| |
Authors: | Reiji Yoshimura Taro Kishi Hikaru Hori Atsuko Ikenouchi-Sugita Asuka Katsuki Wakako Umene-Nakano Nakao Iwata Jun Nakamura |
| |
Institution: | 1. Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu 8078555, Japan;2. Department of Psychiatry, Fujita Health University, Toyoake 4701192, Japan |
| |
Abstract: | ObjectiveOnly two-thirds of depressive patients respond to antidepressant treatment. In recent years, addition of an atypical antipsychotic drug to ongoing treatment with an antidepressant has been considered effective and well-tolerated. In the present study, we compared the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depression.Subjects and methodsTwenty-four patients who met the DSM-IV criteria for major depressive disorder who did not at least two different classes of antidepressants were enrolled in the study. Nine were male and thirteen were female, and their ages ranged from 28 to 66 (mean ± SD = 39 ± 12) years. Patients were prescribed paroxetine (n = 11) or sertraline (n = 13) for 4 weeks. Then, those whose scores on the 17-item Hamilton Rating Scale for Depression (HAMD17) decreased below 50% received adjunctive therapy of aripiprazole for 4 weeks.ResultsAlthough the use of either combination treatment decreased the HAMD17 scores compared to the respective monotherapy, there was no significant difference in HAMD17 scores between the paroxetine plus aripiprazole group and sertraline plus aripiprazole group.ConclusionAripiprazole augmentation therapy with paroxetine or sertraline was equally effective and tolerated in patients with refractory major depressive order. |
| |
Keywords: | HAMD Hamilton Rating Scale for Depression SAS Simpson and Angus Scale SSRI selective serotonin reuptake inhibitor |
本文献已被 ScienceDirect 等数据库收录! |
|